BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 8
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 26
• 29
• 30
• 31

• Pharmacy benefit managers

  July 17, 2024
• GLP-1

  July 17, 2024
• 

  Opinion

  To Weather Layoffs, Biotechs Must Guard Against Lawsuits

  Restructuring can invite lawsuits if companies aren’t careful. Following local, state and federal rules is critical, as is keeping the employee handbook current.

  July 17, 2024

   · 

  3 min read

   · 

  Justin Kozak
• 

  Podcast

  Pfizer’s Oral GLP-1 Push, Lilly Vs. Novo and PBMs Under Pressure

  Pfizer selects its candidate for the oral GLP-1 race as Eli Lilly strives to overtake Novo Nordisk in the injectable weight-loss drug space. Meanwhile, pressure builds to reduce drug prices in the U.S.

  July 17, 2024

   · 

  1 min read

   · 

  Heather McKenzie
• 

  Complete response letters

  Orexo’s Opioid Overdose Nasal Spray Fails FDA Review for Second Time

  Citing the need for another human factor study and more technical data for the final product, the FDA denied approval of Orexo’s nasal spray rescue medication for opioid overdose.

  July 17, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Obesity

  Pfizer’s Once-Daily Weight Loss Pill—Good Play or Bad?

  After nixing a twice-daily version of its oral GLP-1 agonist, Pfizer is hoping to break into the weight-loss space with a once-daily version, but experts question its outlook.

  July 17, 2024

   · 

  4 min read

   · 

  Tyler Patchen
• 

  Drug pricing

  ‘Big Three’ PBMs to Face House Oversight Accountability as Hawaii Court Delivers Legal Victory

  As scrutiny of pharmacy benefit managers mounts, a House committee will hold a hearing on the alleged anticompetitive business practices of these middlemen.

  July 17, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Newly Private NGM Bio Raises $122M for Registrational PSC Study

  After completing a buyout transaction with The Column Group to remove it from the stock exchange, NGM Bio has raised a $122M Series A to fund a registrational study for a rare liver disease drug and a Phase II trial in hyperemesis gravidarum.

  July 17, 2024

   · 

  1 min read

   · 

  Kate Goodwin
• 

  CRISPR

  Ongoing CRISPR Patent Dispute Complicates Licensing but Hasn’t Deterred Gene-Editing Investment

  As the yearslong litigation over ownership of CRISPR gene editing continues, investors have forged ahead with funding the technology’s development by biopharma.

  July 17, 2024

   · 

  8 min read

   · 

  Christoph Schwaiger
• 

  IRA

  AstraZeneca Appeals IRA Loss, Reiterates Constitutional Challenge to Drug Price Negotiations

  AstraZeneca joins Johnson & Johnson and Bristol Myers Squibb in appealing a previous legal loss for its challenge to the government’s drug price-setting program.

  July 17, 2024

   · 

  2 min read

   · 

  Tristan Manalac